Pathway of a Positive Breast Biopsy: Reducing Testing to Treatment Times

October 2016 Vol 7, No 9
Linda Byrd, ADN, RN-BC, CGRN
Emory Saint Joseph's Hospital, Atlanta, GA

Objective: In a suburban community hospital where turnaround times for hormone receptor reports of positive breast biopsies averaged 8 business days, resulting in delayed initiation of treatment, an interdisciplinary breast team led by the breast navigator set out to revise the hormone receptor analysis process to decrease turnaround time by 20%.

Methods: Retrospective and prospective data collection looking at: date of biopsy to report scan date, order date of hormone receptors to report scan date, e-mail notification from outside pathology vendor to scan date, and pathologist review to same-day report scanning. Weekend days were eliminated from all data sets.

Results: During the initial meeting to discuss the project, the interdisciplinary team quickly identified 2 existing barriers to the current pathway: a 2- to 13-day return delivery on pathology slides from outside vendor, and that pathologists were unaware of the web-based results process. Careful data analysis validated the 2 previously identified barriers and did not identify additional barriers. Workflow revisions included improved communication with the outside pathology vendor for overnight slide return when applicable, the addition of e-mail notification from vendor when results are available, increased utilization of a web-based results reporting process, internal modifications of the result-scanning process, and education to the hospital pathologists concerning the process changes. These changes, identified through detailed data collection and interdisciplinary collaboration, yielded a decrease in turnaround time to 4 business days.

Conclusion: As a result of interdisciplinary collaboration, the team achieved a 50% reduction in the number of business days from the time of breast biopsy to availability of hormone receptor results, thus expediting initiation of treatment, decreasing psychosocial distress, and improving patient satisfaction. The team identified the benefit of having a dual role of diagnostic and oncologic navigator who had the ability to identify the issues surrounding turnaround times. This project highlights the importance of nurse navigators and interdisciplinary collaboration and demonstrates how they positively affect healthcare and patient outcomes.

Related Items

Supporting Young Patients With Breast Cancer
By Zeena Nackerdien, PhD
December 2025 Vol 16, No 12
Explore the unique challenges faced by young patients with breast cancer and learn how innovative navigation programs are bridging gaps in care and empowering patients to thrive.
Identification and Treatment of Patients With Hormone Receptor–Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence: monarchE Study Long-Term Outcomes
Special Issues and Supplements
We are pleased to announce the release of our next issue of Clinical Trials to Clinical Practice. This article provides expert commentary from Joyce A. O’Shaughnessy, MD, on the use of endocrine therapy with or without adjuvant abemaciclib for patients with high-risk, hormone receptor (HR)-positive, HER2-negative early breast cancer.
Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path
Resources
The Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path is a resource that oncology nurses and navigators can use to assist patients and caregivers in the fight against early-stage breast cancer. Oncology nurses and navigators guide patients through their treatment journey from time of diagnosis into survivorship, providing education, resources, and support.
Journal of Oncology Navigation & Survivorship
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country